Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFVGXW)

Drug Name

AM-1241 Drug Info

Synonyms

444912-48-5; AM1241; AM-1241; (2-iodo-5-nitrophenyl)(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)methanone; ZUHIXXCLLBMBDW-UHFFFAOYSA-N; AM 1241; GTPL3316; SCHEMBL2030690; CHEMBL408430; CTK8B9184; BDBM21283; MolPort-009-019-655; HMS3651A13; HMS3650F09; MFCD11045986; (R,S)-AM1241; (1-(Methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole); ANW-62168; s1544; AKOS016004972; SB19545; CCG-208738; NCGC00165726-04; NCGC00165726-01; HY-18640; TC-150913; LS-192021; KB-206133; AX8233934; SW219858-1; CS-0011638; ST24033932; Z-3231

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 10141893
CAS Number: CAS 444912-48-5
TTD Drug ID: DMFVGXW

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cannabinoid receptor 2 (CB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[3]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[4]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[5]
KHK-6188	DMF6CTI	Neuropathic pain	8E43.0	Phase 2	[6]
LY-2828360	DMO8IEZ	Pain	MG30-MG3Z	Phase 2	[6]
APD371	DM3XT5V	Crohn disease	DD70	Phase 2	[7]
S-777469	DMZGNOJ	Atopic dermatitis	EA80	Phase 2	[8]
842166X	DMOV0AP	Pain	MG30-MG3Z	Phase 2	[9]
Beta-caryophyllene	DM7583A	Pain	MG30-MG3Z	Phase 2	[10]
Vicasinabin	DMF16CU	Diabetic retinopathy	9B71.0	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Cannabinoid receptor 1 (CB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[12]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[4]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[13]
SR141716A	DMCO5JZ	Obesity	5B81	Approved	[14]
Tebipenem	DMVSX6O	Urinary tract infection	GC08	Phase 3	[15]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[16]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[5]
SR-147778	DMNAECP	Obesity	5B81	Phase 2	[17]
Nimacimab	DM21Z68	Diabetic nephropathy	GB61.Z	Phase 2	[18]
AEF0117	DMQ1GH4	Marijuana use disorder	6C41	Phase 2	[19]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Inhibitor	[2]
Cannabinoid receptor 2 (CB2)	TTMSFAW	CNR2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3316).
2	Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315.
3	Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
4	Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
5	Company report (Gwpharm)
6	Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
9	The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
10	The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
11	Clinical pipeline report, company report or official report of Roche
12	Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
13	Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
14	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
15	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
16	Clinical pipeline report, company report or official report of AstraZeneca (2009).
17	Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
18	Clinical pipeline report, company report or official report of Bird Rock Bio.
19	Clinical pipeline report, company report or official report of Affimed Therapeutics.